AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8622107
Drug: Isepamicin 15
RxNorm normalized name: isepamicin
DrugBank: Isepamicin (DB13540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isepamicin 15 mg/kg once daily
Trial: 2188770
Drug: Epoetin beta
RxNorm normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Epoetin beta (10, 50, 150, and 500 IU/kg) administered intravenously
Trial: 2188770
Drug: Epoetin beta
RxNorm normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Epoetin beta (1000 IU/kg) administered intravenously in an open manner
Trial: 2188770
Drug: Epoetin beta
RxNorm normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Epoetin beta (various doses)
Trial: 6994369
Drug: Iso‐Ameritrat (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iso‐Ameritrat (2.5 mg Isosorbide Dinitrate and 10 mg Pentaerythritol Tetranitrate and 200 mg Meprobamate)
Trial: 6994369
Drug: Ameritrat (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ameritrat (10 mg Pentaerythritol Tetranitrate and 200 mg Meprobamate)
Trial: 30258854
Drug: Higher percentage
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher percentage of daily energy intake from fats
Trial: 24374821
Drug: BMS‐986001 (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS‐986001 (10, 30, 100, 300, 600, and 900 mg fed; 100 and 300 mg fasted)
Trial: 19768533
Drug: Concomitant docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant docetaxel (75 mg/m2 on day 8) plus gemcitabine (1,000 mg/m2 on days 1 + 8) for 8 cycles
Trial: 19768533
Drug: Sequential docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential docetaxel (100 mg/m2 on day 1 for 4 cycles) followed by gemcitabine (1,250 mg/m2 on days 1 + 8 for 4 cycles)
Trial: 17689809
Drug: Probabilistic threshold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probabilistic threshold technique (TT) for measuring maximum acceptable risk increments (MARI) for adverse effects from OA medication.
Trial: 16344838
Drug: Mixed amphetamine
RxNorm normalized name: mixed amphetamine salts 5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed amphetamine salts extended release (MAS XR) 10-60 mg/day (mean dose: 37.2 mg/day)
Trial: 11488519
Drug: Paclitaxel 175
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg/m2 over 1 hour
Trial: 11488519
Drug: Paclitaxel 175
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg/m2 over 3 hours
Trial: 11488519
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of paclitaxel and carboplatin
Trial: 10085709
Drug: Duration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of hemodialysis treatment
Trial: 1098727
Drug: Levamisole 50
RxNorm normalized name: levamisole 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole 50 mg three times a day by mouth for three days every fortnight, starting three days before surgery
Trial: 19307225
Drug: Antireflux treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antireflux treatment
Trial: 8458448
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate (LA) depot (Enantone Depot, Takeda, Italy) administered preoperatively
Trial: 2429085
Drug: Methyldopa (500‐1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyldopa (500‐1000 mg daily)
Trial: 30565854
Drug: Rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 20 mg day−1 for 4 weeks
Trial: 24714541
Drug: HMB-FA (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB-FA (3 g) and ATP (400 mg) supplementation
Trial: 24706266
Drug: Synbiotic bread
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic bread (1 × 10(8) CFU Lactobacillus sporogenes and 0.07 g inulin per 1 g)
Trial: 24706266
Drug: Probiotic bread
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic bread (1 × 10(8) CFU Lactobacillus sporogenes per 1 g)
Trial: 21450196
Drug: Mental practice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mental practice intervention embedded in regular therapy
Trial: 21450196
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy as usual (control group)
Trial: 20450590
Drug: Calcium-Magnesium infusion
RxNorm normalized name: CALCIUM/MAGNESIUM/POTASSIUM/SODIUM OXYBATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-Magnesium infusion
Trial: 20450590
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (normal saline)
Trial: 17364394
Drug: DAART (Directly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAART (Directly Administered Antiretroviral Therapy)
Trial: 10325288
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (diagnostic laparoscopy only, 47 patients)
Trial: 8961453
Drug: Pain facility
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain facility treatment
Trial: 1763680
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no immuno-suppressive treatment)
Trial: 29530858
Drug: Iclaprim (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iclaprim (80 mg) administered intravenously every 12 h for 5 to 14 days
Trial: 29530858
Drug: Vancomycin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (15 mg/kg of body weight) administered intravenously every 12 h for 5 to 14 days
Trial: 26560249
Drug: Pulmonary artery
RxNorm normalized name: Pulmonary artery blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulmonary artery pressure guided management (treatment group)
Trial: 20546269
Drug: Euglycaemia (5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycaemia (5.0 mmol/l)
Trial: 20546269
Drug: Hyperglycaemia (11.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycaemia (11.0 mmol/l)
Trial: 19034035
Drug: Clopidogrel 37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 37.5 mg
Trial: 9507380
Drug: Leukapheresis initiated
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Leukapheresis initiated based on CD34+ blood level exceeding 20,000 CD34+/ml
Trial: 9507380
Drug: Leukapheresis for
RxNorm normalized name: AUTOLOGOUS CD4+ AND CD8+ T CELLS OBTAINED BY LEUKAPHERESIS, TRANSDUCED WITH AN HIV-DERIVED SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING AN ENHANCED-AFFINITY T CELL RECEPTOR (TCR) SPECIFIC FOR THE HUMAN MELANOMA ANTIGEN A4 (MAGE FAMILY MEMBER A4, A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukapheresis for high-level mobilizers (> 80,000 CD34+ cells/ml)
Trial: 9507380
Drug: Leukapheresis for
RxNorm normalized name: AUTOLOGOUS CD4+ AND CD8+ T CELLS OBTAINED BY LEUKAPHERESIS, TRANSDUCED WITH AN HIV-DERIVED SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING AN ENHANCED-AFFINITY T CELL RECEPTOR (TCR) SPECIFIC FOR THE HUMAN MELANOMA ANTIGEN A4 (MAGE FAMILY MEMBER A4, A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukapheresis for low-level mobilizers (< 40,000 CD34+ cells/ml)
Trial: 8064949
Drug: Maloprim (pyrimethamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maloprim (pyrimethamine 12.5 mg + dapsone 100 mg)
Trial: 30183875
Drug: Ear acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ear acupuncture (Treatment)
Trial: 25042488
Drug: Chondroprotector АРТРА
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chondroprotector АРТРА with melaxen (melatonin 3 mg)
Trial: 20647201
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment with zidovudine, lamivudine, and efavirenz therapy within 2 weeks after enrollment
Trial: 20647201
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment starting when CD4+ T-cell count fell to 200 or less or when clinical AIDS developed
Trial: 20647201
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment with zidovudine, lamivudine, and efavirenz therapy
Trial: 16003229
Drug: Corticosteroid rejection
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid rejection therapy in CSWD patients
Trial: 11809343
Drug: HRT 1
RxNorm normalized name: FEMHRT 1/5 TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT 1 (1 mg 17beta‐estradiol daily + 0.025 mg gestodene cyclically every month)
Trial: 11809343
Drug: HRT 2
RxNorm normalized name: EE/NETHDRONE (EQV-FEMHRT 2.5/0.5) TAB,28
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT 2 (1 mg 17beta‐estradiol daily + 0.025 mg gestodene cyclically every third month)
Trial: 25195125
Drug: Atorvastatin only
RxNorm normalized name: Atorvastatin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin only
Trial: 25195125
Drug: Ivabradine and
RxNorm normalized name: carvedilol and ivabradine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine and atorvastatin
Trial: 25195125
Drug: No study
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No study drugs
Trial: 22227183
Drug: 1,25-dihydroxyvitamin D
RxNorm normalized name: 1,25-dihydroxyvitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,25-dihydroxyvitamin D (1,25(OH)₂D), plasma Ca²⁺, daily physical activity
Trial: 1696662
Drug: verapamil 160
RxNorm normalized name: verapamil 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: verapamil 160 mg b.i.d.
Trial: 7438948
Drug: Dibenzyline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dibenzyline (10 mg doses orally, four and eight hours after surgery)
Trial: 28243722
Drug: Re-irradiation with
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-irradiation with standard dose
Trial: 24321380
Drug: Pharmacological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological therapy alone (Control group)
Trial: 21942813
Drug: Iron-rich bread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-rich bread (3-4 slices daily for 6 weeks)
Trial: 21942813
Drug: Control bread
RxNorm normalized name: Eazi-Breed CIDR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control bread (3-4 slices daily for 6 weeks)
Trial: 17479606
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide plus inhaled formoterol fumarate
Trial: 17479606
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide and oral montelukast sodium therapy
Trial: 15727375
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg triamcinolone intra‐articular injection
Trial: 15727375
Drug: triamcinolone oral
RxNorm normalized name: triamcinolone Oral Paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triamcinolone oral tablets
Trial: 1362568
Drug: Taxol administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxol administered as a 120 h infusion at 36 mg/m2/d
Trial: 1362568
Drug: Taxol administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxol administered as a 120 h infusion at 30 mg/m2/d
Trial: 1362568
Drug: Taxol administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxol administered as a 120 h infusion
Trial: 16028649
Drug: Dexamethasone treatment
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone treatment (0.25 mg/kg on days 1-7, 0.12 mg/kg on days 8-14, 0.05 mg/kg on days 15-21, 0.02 mg/kg on days 21-28)
Trial: 16028649
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no dexamethasone treatment)
Trial: 9788977
Drug: Human parathyroid
RxNorm normalized name: HUMAN PARATHYROID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human parathyroid hormone 1-34 (hPTH 1-34)
Trial: 9788977
Drug: Markers of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Markers of bone formation during the first 3 months of PTH treatment
Trial: 9788977
Drug: Markers of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Markers of bone resorption during the first 3 months of PTH treatment
Trial: 7587796
Drug: Nicotine (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (12 mg chewing gum)
Trial: 2262701
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of metoclopramide and ranitidine
Trial: 7377659
Drug: Methylprednisolone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (30 mg/kg IV, repeated doses every six hours)
Trial: 31049835
Drug: High temperature
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High temperature treatment (30–40 °C) for 15 days
Trial: 27133000
Drug: Standard-of-care therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care therapy with video models
Trial: 27133000
Drug: Standard-of-care therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care therapy without videos
Trial: 25412614
Drug: Medical Treatment
RxNorm normalized name: Medical air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical Treatment Only (MTO)
Trial: 19938897
Drug: Fampridine-SR (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fampridine-SR (10 mg twice daily)
Trial: 19938897
Drug: Fampridine-SR (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fampridine-SR (30 mg twice daily)
Trial: 19938897
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg on treatment day 5)
Trial: 17122715
Drug: General antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General antidepressant requests
Trial: 17122715
Drug: Brand-specific antidepressant
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brand-specific antidepressant requests
Trial: 17122715
Drug: Antidepressant medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant medication requests
Trial: 15301041
Drug: Oral testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral testosterone undecanoate (TU) 40 mg daily
Trial: 15301041
Drug: Intramuscular depot
RxNorm normalized name: Primoteston Depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular depot sustanon 50 (SUS), 4 weekly
Trial: 30919407
Drug: ASN002 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASN002 20 mg
Trial: 30919407
Drug: ASN002 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASN002 40 mg
Trial: 30919407
Drug: ASN002 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASN002 80 mg
Trial: 25305090
Drug: Ticagrelor 180
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 180 mg loading dose (LD)/90 mg twice-daily maintenance dose (MD)
Trial: 25305090
Drug: Clopidogrel 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 600 mg LD/75 mg once-daily MD
Trial: 29954374
Drug: Low tocotrienol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low tocotrienol (430 mg tocotrienol/day from DeltaGold 70 containing 300 mg tocotrienol)
Trial: 29954374
Drug: High tocotrienol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High tocotrienol (860 mg tocotrienol/day from DeltaGold 70 containing 600 mg tocotrienol)
Trial: 27363723
Drug: Steroid-releasing implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-releasing implant
Trial: 17216745
Drug: Phenylpropanolamine (PPA)
DrugBank: Phenylpropanolamine (DB00397)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylpropanolamine (PPA) 50 mg twice daily for seven days
Trial: 12628617
Drug: Piracetam (4.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam (4.8 g/day)
Trial: 12628617
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba (120 mg/day)
Trial: 9398896
Drug: Eradication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradication therapy (antibiotics)
Trial: 1593661
Drug: Enriched tapering
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enriched tapering and aftercare assistance program (available to 58 clients)
Trial: 6379122
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (MVPP)
Trial: 6379122
Drug: Chemotherapy followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy followed by radiotherapy (MVPP + radiotherapy)
Trial: 28429147
Drug: Modafinil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (200 mg/day for 15 days)
Trial: 28929697
Drug: Berberine 300
RxNorm normalized name: berberine
DrugBank: Berberine (DB04115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berberine 300 mg (tid) in addition to general therapy
Trial: 28929697
Drug: General therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General therapy according to the latest guidelines
Trial: 22112606
Drug: Ritonavir‐boosted protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir‐boosted protease inhibitor (PI/r)
Trial: 19528867
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment - dynamic stretches only
Trial: 17558827
Drug: Bupropion 300
RxNorm normalized name: buPROPion 300 mg/24 hours oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion 300 mg/day with Cognitive Behavioral Therapy (CBT)
Trial: 17558827
Drug: Bupropion 300
RxNorm normalized name: buPROPion 300 mg/24 hours oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion 300 mg/day with Supportive Therapy (ST)
Trial: 17558827
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with Cognitive Behavioral Therapy (CBT)
Trial: 17558827
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with Supportive Therapy (ST)
Trial: 15366592
Drug: Integrative Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative Chinese and Western medicine (ICWM) with Kangmin Xiaoban Yin for 7-10 days
Trial: 15366592
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Western routine therapy)
Trial: 9074535
Drug: Metoprolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (50 mg orally 12 hr and 1 hr before the study)
Trial: 9074535
Drug: Metoprolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (50 mg orally 12 hr and 1 hr before the study) with dipyridamole
Trial: 22541840
Drug: Losartan Potassium
RxNorm normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan Potassium Tablets 50 mg
Trial: 22541840
Drug: Cozaar® Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cozaar® Tablets 50 mg
Trial: 17526461
Drug: MAOx (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAOx (1.2 g)
Trial: 12948801
Drug: Hypnotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypnotic treatment (zolpidem, triazolam, zopiclone, brotizolam)
Trial: 9356866
Drug: silymarin (210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: silymarin (210 mg/day)
Trial: 9356866
Drug: no drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no drug treatment (control group)
Trial: 8222746
Drug: Ciprofloxacin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (2 mg/ml) ear drops twice daily for 7 days
Trial: 8222746
Drug: Combined antibiotic
RxNorm normalized name: combinations of different antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined antibiotic (oxytetracycline 5 mg/ml, polymyxin B 10,000 units/ml, hydrocortisone 15 mg/ml) ear drops twice daily for 7 days
Trial: 3511930
Drug: Metoprolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (200 mg slow release tablets once daily for at least 2 weeks, plus 15 mg i.v. shortly before anaesthesia)
Trial: 3511930
Drug: Placebo (tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (tablets and saline)
Trial: 22588156
Drug: Tasisulam sodium
RxNorm normalized name: Tasisulam
DrugBank: Tasisulam (DB11941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tasisulam sodium (LY573636 sodium) administered as a 2-hour infusion every 21 days at a Cmax target dose of 420 µg/ml